Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2031)	1/30/2004 4:14:15 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3044

[I picked up the following from the Yahoo! board] Thanks for passing it on. I always like an unknown.

To: Icebrg who wrote (2031)	2/3/2004 4:35:03 PM
From: tuck	Respond to of 3044

[MLN 4760: ACE2 inhibitor for SARS and cardiovascular indications] >>J Biol Chem. 2004 Jan 30 [Epub ahead of print] ACE2 structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA, Pantoliano MW. Drug Discovery, Millennium Pharmaceuticals Inc., Cambridge, MA 02139. The angiotensin converting enzyme-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH + E zinc-binding consensus sequence. ACE2 has been implicated in the regulation of heart function, and also, as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2 and 3.0 resolution, respectively. Comparison of these structures revealed a large inhibitor dependent hinge bending movement of one catalytic subdomain relative to the other (~16), which brings important residues into position for catalysis. The binding of the potent inhibitor, (S,S) 2-{1-carboxy-2-[3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino}-4-methyl-pentanoic acid (MLN-4760), makes key binding interactions within the active site, and offers insights regarding the action of residues involved in catalysis and substrate specificity. A few active site residue substitutions for ACE2, relative to ACE, appear to eliminate the S2 substrate binding subsite, and account for the observed reactivity change from the peptidyl-dipeptidase activity of ACE to the carboxypeptidase activity of ACE2.<< The full text is available for free in PDF format: jbc.org Cheers, Tuck

To: Icebrg who wrote (2031)	2/9/2004 6:27:05 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Generex Appoints Dr. Douglas Powell as Director of Immunobiology Monday February 9, 10:51 am ET Former Senior Scientist at Millennium Pharmaceuticals to Lead Development of Cancer and Infectious Disease Programs at Company's Subsidiary [Should we understand this to mean that Millennium has decided to stop their HIV-program(s)? Not that I knew that there was one.] TORONTO, Feb. 9 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), announced today the appointment of Douglas Powell, Ph. D., formerly a Senior Scientist at Millennium Pharmaceuticals, Inc., to be Director of Immunobiology at Antigen Express, its immunomedicines subsidiary near Boston. Dr. Powell will coordinate development of novel T helper cell vaccine technologies in human T lymphocytes and dendritic cells for treatment of cancer and infectious diseases, and to combat bioterrorism agents. Anna Gluskin, President & Chief Executive Officer of Generex, said, "We are pleased to have Dr. Powell join our scientific team. His substantial accomplishments, and well-deserved reputation as a creative and productive biotech inventor, participating in about 100 patent applications, position him for similarly great achievements with us." "I am excited to join this very strong Antigen Express-Generex product development team," said Dr. Powell. "I have been impressed by the technology and believe we are well positioned to capitalize on large markets for unmet medical needs." While at Millennium, Dr. Powell was the Principal Investigator in charge of the HIV program utilizing gene arrays to identify cellular targets for therapeutic intervention. He led the filing of 60 patents on methods and compositions for treating AIDS and HIV-related disorders. He also established multiple collaborative research programs with investigators at Harvard and Emory Universities, The University California, Irvine and The University Hospital Zurich, Switzerland. biz.yahoo.com